ClinicalTrials.gg
RecruitingNCT07593625EVOLUTIONT1DUpdated Sep 10, 2026

Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D

An interventional study of Omnipod M System and Omnipod S in Type 1 Diabetes, Type 1 Diabetes Mellitus and Diabetes (DM), sponsored by Insulet Corporation. Recruiting at 1 site in New Zealand. Open to participants aged 2 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Insulet Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
2 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Insulet Corporation.

Planned enrollment
6th of 11
80 · median 80
Started
2026
with 2 others
No phase
11 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, and was the 14th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, or all of them as a file.
02

Study summary

Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes. This study will enroll up to 80 participants to have a minimum of 48 participants to initiate the use of Omnipod. The study will include hotel and outpatient evaluation periods.

03

Conditions studied

  • Type 1 Diabetes
  • Type 1 Diabetes Mellitus
  • Diabetes (DM)

Keywords

  • Type 1 Diabetes
  • T1D
  • Omnipod
  • Omnipod M
  • Automated Insulin Delivery System
  • AID
  • fully closed loop
  • FCL
  • Omnipod S
  • Bolus
04

Who can participate

Ages eligible
2 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at time of consent 2-70 years (inclusive)
  • Type 1 diabetes diagnosis for at least 6 months, for those aged 8-70 years, or 3 months for those aged 2-7 years, based on Investigator assessment
  • Basal/Bolus insulin delivery via multiple daily injections or insulin pump with or without automation
  • Willing to use the following types of U-100 insulin during the study: Humalog U-100, Novorapid or their generic equivalents
  • Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
  • If using noninsulin glucose-lowering medications or weight reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.
  • Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
  • Willing to wear the system continuously throughout the study
  • Willing and able to sign the Form (ICF) or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from participants per local regulatory requirements
  • Able to read and understand English
  • If of , willing and able to have pregnancy testing

Exclusion criteria

Exclusion Criteria:

  • Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated , unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.
  • Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or arrhythmias requiring intervention within the 12 months prior to screening
  • Any planned surgery during the study which could be considered major in the opinion of the Investigator
  • History of more than 1 severe hypoglycaemia in the past 6 months. Severe hypoglycaemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
  • History of more than 1 diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
  • Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of
  • Use of hydroxyurea
  • Plans to receive blood transfusion over the course of the study
  • Has taken systemic (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
  • Use of non-insulin glucose-lowering medication or weight loss medications other than metformin and/or GLP1, in the 4 weeks prior to screening. Participants taking metformin and/or GLP1 should remain on a steady dose without dose increases during study participation
  • Pregnant or lactating, or is of and not using an acceptable form of (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilisation such as tubal ligation or hysterectomy, or vasectomised partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months ).
  • In the past 30-days, has participated in a clinical study using any drug or any investigational device that in the opinion of the investigator may have therapeutic impact on their diabetes management. Additionally, may not intend to participate in any other interventional clinical study during this study period
  • Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
  • Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Adults with T1D using Omnipod M

    Device: Omnipod M System

  • Experimental
    Adults and pediatrics with T1D using Omnipod S

    Device: Omnipod S

Interventions

  • DeviceOmnipod M System

    Participants will use the Omnipod M System

  • DeviceOmnipod S

    Participants will use the Omnipod S System

06

What researchers measure

Primary outcomes

  1. Percentage of time <54 mg/dL

    CGM percent time \<54 mg/dL compared to standard therapy

    Time frame: 72-hour Omnipod M Hotel Period

  2. Percentage of time <70 mg/dL

    CGM percent time \<70 mg/dL compared to standard therapy

    Time frame: 72-hour Omnipod M Hotel Period

  3. Percentage of time >180 mg/dL

    CGM percent time \>180 mg/dL compared to standard therapy

    Time frame: 72-hour Omnipod M Hotel Period

  4. Percentage of time <54 mg/dL

    CGM percent time \<54 mg/dL compared to standard therapy

    Time frame: 4-week Omnipod M outpatient

  5. Percentage of time <54 mg/dL

    CGM percent time \<54 mg/dL compared to initial data collection phase

    Time frame: Final 3 weeks of Omnipod S outpatient

  6. Percentage of time <70 mg/dL

    CGM percent time \<70 mg/dL compared to standard therapy

    Time frame: 4-week Omnipod M outpatient

  7. Percentage of time <70 mg/dL

    CGM percent time \<70 mg/dL compared to initial data collection phase

    Time frame: Final 3-weeks Omnipod S outpatient

  8. Percentage of time >180 mg/dL

    CGM percent time \>180 mg/dL compared to standard therapy

    Time frame: 4-week Omnipod M outpatient

  9. Percentage of time >180 mg/dL

    CGM percent time \>180 mg/dL compared to initial data collection phase

    Time frame: Final 3-weeks Omnipod S outpatient

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 7 months is below that.

Counting every sponsor, half of 955 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartActual
May 25, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 1, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07593625
Responsible party
Sponsor
First posted
May 18, 2026
Start date
May 25, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Trang Ly, MBBS, PhD
Contact
APClinical@insulet.com
978-600-7000
Bonnie Dumais, RN
Contact
APClinical@insulet.com
978-600-7000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion